港股异动 | 信达生物(01801)涨超3% 与Spero就IBI355达成独家许可协议将于明年初启动治疗SjD临床II期研究

智通财经网07-15

智通财经APP获悉，信达生物(01801)涨超3%，截至发稿，涨3.28%，报93港元，成交额1.01亿港元。消息面上，7月14日，据信达生物官微消息，公司与Spero Therapeutics, Inc.(纳斯达克股票代码：SPRO，“Spero”)宣布，双方就IBI355(Spero研发代号：SP001)——第三代Fc沉默型抗CD40L抗体——达成独家许可协议。根据协议，信达生物授予...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2651384024?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20260715/20260715093749_87050.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2026-07-15 09:35","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2651384024","market":"fut","top_or_hot":-1,"title":"港股异动 | 信达生物(01801)涨超3% 与Spero就IBI355达成独家许可协议 将于明年初启动治疗SjD临床II期研究","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，信达生物(01801)涨超3%，截至发稿，涨3.28%，报93港元，成交额1.01亿港元。消息面上，7月14日，据信达生物官微消息，公司与Spero Therapeutics,  Inc.(纳斯达克股票代码：SPRO，“Spero”)宣布，双方就IBI355(Spero研发代号：SP001)——第三代Fc沉默型抗CD40L抗体——达成独家许可协议。根据协议，信达生物授予...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1467631.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 信达生物(01801)涨超3% 与Spero就IBI355达成独家许可协议 将于明年初启动治疗SjD临床II期研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 信达生物(01801)涨超3% 与Spero就IBI355达成独家许可协议 将于明年初启动治疗SjD临床II期研究\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-15 09:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1467631.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，信达生物(01801)涨超3%，截至发稿，涨3.28%，报93港元，成交额1.01亿港元。消息面上，7月14日，据信达生物官微消息，公司与Spero Therapeutics,  Inc.(纳斯达克股票代码：SPRO，“Spero”)宣布，双方就IBI355(Spero研发代号：SP001)——第三代Fc沉默型抗CD40L抗体——达成独家许可协议。根据协议，信达生物授予...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1467631.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KCAI","symbol_name":"KraneShares China Alpha Index ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1467631.html","article_id":"2651384024","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20260715/20260715093749_87050.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651384024","pubTimestamp":1784079328,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"信达生物(01801)涨超3%，截至发稿，涨3.28%，报93港元，成交额1.01亿港元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"KCAI":"KraneShares China Alpha Index ETF","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","BK1589":"北水核心资产","BK4588":"碎股","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1161":"生物科技","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK4585":"ETF&股票定投概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","VXUS":"国际股票ETF-Vanguard","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","01801":"信达生物","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1583":"高瓴概念","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC"},"translate_title":"Changes in Hong Kong stocks | Innovent Biologics (01801) rose by more than 3% and reached an exclusive license agreement with Spero for IBI355 and will start a phase II clinical study for the treatment of SjD early next year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KCAI":1.5,"KURE":0.6,"01801":1.5,"VXUS":1.5},"content_text":"智通财经APP获悉，信达生物(01801)涨超3%，截至发稿，涨3.28%，报93港元，成交额1.01亿港元。消息面上，7月14日，据信达生物官微消息，公司与Spero Therapeutics,  Inc.(纳斯达克股票代码：SPRO，“Spero”)宣布，双方就IBI355(Spero研发代号：SP001)——第三代Fc沉默型抗CD40L抗体——达成独家许可协议。根据协议，信达生物授予Spero在大中华区以外全球范围内开发、研究、生产和商业化IBI355的独家权益；信达生物保留该产品在大中华区的权益。Spero计划于2027年第二季度启动IBI355治疗IgG4-RD患者的临床II期研究；信达生物计划于2027年初前在中国启动IBI355治疗SjD的临床II期研究。根据协议条款，信达生物将获得首付款，和开发、注册及销售相关的里程碑付款，交易总额约11亿美元。信达生物同时还将获得未来基于该产品净销售额的梯度式销售分成。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651384024","isCrawlerRequest":true}

港股异动 | 信达生物(01801)涨超3% 与Spero就IBI355达成独家许可协议 将于明年初启动治疗SjD临床II期研究

精彩评论

港股异动 | 信达生物(01801)涨超3% 与Spero就IBI355达成独家许可协议将于明年初启动治疗SjD临床II期研究